The effect of acetylsalicylic acid on the release rates of leukotrienes B4 and C4 from cultured skin melanocytes of active vitiligo
- PMID: 15494818
The effect of acetylsalicylic acid on the release rates of leukotrienes B4 and C4 from cultured skin melanocytes of active vitiligo
Abstract
Objective: The aim of this study is to investigate the effect of the non-steroidal anti-inflammatory agent, acetylsalicylic acid (ASA), otherwise known as aspirin, at different concentrations on the release rates of the pro-inflammatory mediators, leukotriene B4 (LTB4) and leukotriene C4 (LTC4) from in vitro cultured melanocytes obtained from normal pigmented skin of patients with active vitiligo.
Methods: This study was carried out between April, 2000 and September, 2001, at The Vitiligo Unit, King Abdul-Aziz University Medical Center, Jeddah, Kingdom of Saudi Arabia. Skin biopsies were obtained from patients with active vitiligo (n=7) of different extent and duration, and normal healthy age-matched individuals (n=7) serving as control were recruited to the study. The release rates of LTB4 and LTC4 were determined before and after the addition of the ASA at 3 different concentrations (15, 75, 150 microg/ml) in the primary skin melanocytes culture medium using a commercially available kit based on radioimmunoassay method.
Results: Following the ASA treatment at 3 different concentrations (15, 75 and 150 microg/ml), the release rates of LTB4 and LTC4 were increased from melanocytes of the normal individuals (13%, 7.5% and 30%; 7.2%, 51.4% and 60.7%, p<0.001). However, in patients with active vitiligo, the release rate of LTB4 from melanocytes was decreased (2.9%, 14.4% and 7.4%, p<0.05), whereas that of LTC4 was increased (3.9%, 93.8% and 101.4%, p<0.001).
Conclusion: Acetylsalicylic acid at therapeutic concentrations can regulate the release rates of LTB4 and LTC4 from cultured skin melanocytes of normal and active vitiligo subjects.
Similar articles
-
Short- and long-term effects of acetylsalicylic acid treatment on the proliferation and lipid peroxidation of skin cultured melanocytes of active vitiligo.Saudi Med J. 2004 Nov;25(11):1656-63. Saudi Med J. 2004. PMID: 15573197
-
Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients.Saudi Med J. 2005 Jul;26(7):1085-91. Saudi Med J. 2005. PMID: 16047057 Clinical Trial.
-
Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment.Saudi Med J. 2005 May;26(5):799-805. Saudi Med J. 2005. PMID: 15951873 Clinical Trial.
-
[Leukotrienes as inflammation mediators].Postepy Hig Med Dosw. 2003;57(5):593-610. Postepy Hig Med Dosw. 2003. PMID: 14737972 Review. Polish.
-
Decreased phenylalanine uptake and turnover in patients with vitiligo.Mol Genet Metab. 2005 Dec;86 Suppl 1:S27-33. doi: 10.1016/j.ymgme.2005.07.023. Epub 2005 Sep 6. Mol Genet Metab. 2005. PMID: 16143555 Review.
Cited by
-
Metabolic pathways of eicosanoids-derivatives of arachidonic acid and their significance in skin.Cell Mol Biol Lett. 2025 Jan 17;30(1):7. doi: 10.1186/s11658-025-00685-y. Cell Mol Biol Lett. 2025. PMID: 39825220 Free PMC article. Review.
-
Aspirin in dermatology: Revisited.Indian Dermatol Online J. 2015 Nov-Dec;6(6):428-35. doi: 10.4103/2229-5178.169731. Indian Dermatol Online J. 2015. PMID: 26753146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous